Black checkmark with a sparkle and a curved line underneath on a white background.
Company

SIGA TECHNOLOGIES INC

Ticker
SIGA
Sector
Industry
Report date
November 10, 2026
Valye AI Score

94

Very high visibility
Recent developments
Recent developments summary

Recent developments include SIGA's announcement of a $15 million procurement contract and financial results for Q3 2026, and a Canadian defense contract worth up to $15 million for its smallpox antiviral product.

Recent developments:
  • SIGA reported a $15 million procurement contract and financial results for the three and nine months ended September 30, 2026 [N2].
  • The company won a Canadian defense contract worth up to $15 million for its smallpox antiviral product [N3].
  • SIGA held its Q3 2026 earnings call discussing operational and financial updates [N1].
Overview

SIGA Technologies, Inc. develops and commercializes antiviral drugs, with its lead product TPOXX® approved for treatment of smallpox and related orthopoxviruses. The company markets oral and intravenous formulations primarily to government entities, including the U.S. Strategic National Stockpile. Regulatory approvals extend beyond the U.S. to Europe, Canada, the UK, and Japan, with some indications authorized under exceptional circumstances requiring ongoing data collection. SIGA's business model centers on government procurement contracts, including a substantial BARDA contract and Department of Defense agreements. The company outsources manufacturing to contract organizations and manages international sales through agreements such as with Meridian Medical Technologies. Recent regulatory reviews focus on the mpox indication, with potential label changes under consideration. Financially, SIGA maintains strong liquidity and reports modest net losses in recent periods.

Executive summary

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company specializing in antiviral drugs, primarily TPOXX® (tecovirimat) for smallpox treatment. The company sells oral and intravenous formulations mainly to U.S. and international governments. TPOXX® holds FDA approval and regulatory approvals in multiple jurisdictions, with ongoing regulatory reassessments particularly concerning the mpox indication. SIGA operates under significant government procurement contracts, including a major BARDA contract with potential payments up to $630 million. The company relies on contract manufacturers for production and maintains strong liquidity as of September 30, 2026. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice [S2].

Scenarios for SIGA

Bull case model:

SIGA benefits from its unique position as a supplier of an FDA-approved antiviral for smallpox, supported by substantial government contracts and international regulatory approvals. The company's strong liquidity and ongoing clinical and regulatory activities, including potential label expansions, support its operational stability. Continued government demand for stockpiling and international sales agreements underpin revenue visibility. The company's outsourcing manufacturing model allows operational flexibility and cost control.

Bear case model:

SIGA faces risks from regulatory reassessments, particularly the potential withdrawal of the mpox indication by EMA and MHRA, which could impact market opportunities. The company's financial performance includes net losses and reliance on government contracts that may be subject to discretionary funding and option exercises. Manufacturing dependence on third parties introduces supply chain risks. Macroeconomic factors such as tariffs and trade policies could increase costs. Limited diversification beyond TPOXX® and government customers may constrain growth potential.

Moat:

SIGA's moat derives from its FDA and international regulatory approvals for TPOXX®, a specialized antiviral drug for smallpox, a rare but high-consequence disease. The company's extensive government procurement contracts, including a large BARDA contract, provide a stable revenue base. Regulatory barriers and the rarity of the disease limit competition. Additionally, SIGA's established relationships with government stockpiles and its reliance on contract manufacturing reduce capital intensity. However, the company's dependence on government contracts and regulatory approvals for continued market access represent critical factors in its competitive positioning.

Risks overview
Risks summary
The primary risks for SIGA involve regulatory reassessments that may alter product indications and the company's reliance on government contracts subject to funding discretion.
Risks details:

• Regulatory Risk: Ongoing regulatory reassessments by EMA and MHRA could lead to withdrawal or modification of product indications, notably for mpox, affecting market access and revenues.
• Contract Dependency: SIGA's revenues heavily depend on government procurement contracts, including BARDA and DoD, which may be subject to discretionary funding and option exercises.
• Manufacturing Risk: The company relies entirely on third-party contract manufacturers, exposing it to supply chain disruptions and quality control risks.
• Financial Performance: Recent financial results show net losses and modest earnings per share, indicating challenges in profitability.
• Macroeconomic and Trade Risks: Tariffs, trade policies, and geopolitical factors could increase raw material and manufacturing costs, impacting margins.

FINAL FORECAST FOR SIGA

Final take one line
SIGA Technologies operates with high transparency around its antiviral product TPOXX®, supported by government contracts and regulatory approvals, with key risks centered on regulatory reassessments and contract dependency.
Final take 12 to 24 month view

Business trends: Continued government procurement contracts and regulatory reassessments shape SIGA's operational environment.
Execution milestones: Submission of supplemental NDA for smallpox post-exposure prophylaxis and outcomes of EMA and MHRA reassessments.
Key risks: Regulatory changes affecting product indications, reliance on government contracts, and manufacturing supply chain dependencies.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

94
LLM visibility overview
LLM Visibility known facts
  • SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on antiviral drugs, primarily TPOXX® (tecovirimat) for treatment of smallpox and related orthopoxviruses [S1].
  • The company sells oral TPOXX® and intravenous (IV) TPOXX® formulations primarily to the U.S. Government and international governments, sometimes through distributors [S1].
  • Oral TPOXX® was FDA approved in July 2018 for smallpox treatment; IV TPOXX® was FDA approved in May 2022 [S1].
  • Oral TPOXX® has regulatory approvals from EMA, Health Canada, MHRA (UK), and PMDA (Japan) for smallpox and related indications; EMA and MHRA granted marketing authorizations under exceptional circumstances requiring ongoing data collection and annual reassessments [S1].
  • The EMA's CHMP initiated a referral procedure in July 2025 reviewing Tecovirimat-SIGA's effectiveness for mpox, with a recommendation expected in March 2026; the mpox indication may be withdrawn while other indications are expected to be maintained [S1].
  • SIGA completed immunogenicity and safety trials for potential FDA label expansion of oral TPOXX® for smallpox post-exposure prophylaxis, targeting a supplemental NDA submission within twelve months [S1].
  • The company relies on contract manufacturing organizations (CMOs) for production of TPOXX®, with no internal manufacturing infrastructure [S1].
  • SIGA has a significant contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for delivery and manufacture of oral and IV TPOXX®, with total payments contemplated up to approximately $630 million, including base period and exercised options [S1].
  • As of December 31, 2025, SIGA had delivered substantial courses of oral and IV TPOXX® to the U.S. Strategic National Stockpile under the BARDA contract [S1].
  • SIGA had sales of approximately $10 million with the U.S. Department of Defense in 2024, mostly oral TPOXX® [S1].
  • International sales were $5.8 million in 2025 to one country, and $23 million in 2024 to 13 countries, primarily oral TPOXX® [S1].
  • SIGA has an International Promotion Agreement with Meridian Medical Technologies for advertising, promotion, and sales of oral TPOXX® in certain territories, with SIGA retaining ownership and regulatory responsibilities [S1].
  • Recent news reports include a $15 million procurement contract announcement and financial results for Q3 2026, and a Canadian defense contract worth up to $15 million for smallpox antiviral [N2][N3].
  • As of September 30, 2026, SIGA reported cash and equivalents of $116.4 million, current assets of $165.5 million, current liabilities of $6.7 million, a current ratio of 24.57, and a cash ratio of 17.27, indicating strong liquidity [S2].
  • Net income for the nine months ended September 30, 2026, was a loss of approximately $2.9 million, with basic and diluted EPS of -$0.04 [S2].
Sources
Sources - Context summary

Generated 2026-11-10

Sources - Earning calls
  • N1
  • N4
  • N5
  • N6
  • N7
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-10 | 10-K
  • S2 | 2026-11-09 | 10-Q
Sources - News headlines
  • N1 | 2026-11-10 | www.nasdaq.com | SIGA (SIGA) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/siga-siga-q3-2026-earnings-call-transcript
  • N2 | 2026-11-09 | www.nasdaq.com | SIGA Technologies, Inc. Reports $15 Million Procurement Contract and Financial Results for Three and Nine Months Ended September 30, 2026 | https://www.nasdaq.com/articles/siga-technologies-inc-reports-15-million-procurement-contract-and-financial-results-three
  • N3 | 2026-10-28 | www.nasdaq.com | SIGA Wins Canadian Defence Contract Worth Up To $15M For Smallpox Antiviral; Stock Up | https://www.nasdaq.com/articles/siga-wins-canadian-defence-contract-worth-15m-smallpox-antiviral-stock
  • N4 | 2026-08-14 | www.nasdaq.com | SIGA (SIGA) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/siga-siga-q2-2026-earnings-call-transcript
  • N5 | 2026-08-07 | www.nasdaq.com | Siga Technologies Q2 Earnings Call Highlights | https://www.nasdaq.com/articles/siga-technologies-q2-earnings-call-highlights
  • N6 | 2026-05-09 | www.nasdaq.com | Siga Technologies Q1 Earnings Call Highlights | https://www.nasdaq.com/articles/siga-technologies-q1-earnings-call-highlights
  • N7 | 2026-05-07 | www.nasdaq.com | SIGA (SIGA) Q1 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/siga-siga-q1-2026-earnings-call-transcript
  • N8 | 2026-03-11 | www.nasdaq.com | SIGA Q4 And FY25 Revenue Declines | https://www.nasdaq.com/articles/siga-q4-and-fy25-revenue-declines
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine